April 17, 2017
Article
The investigational tyrosine kinase inhibitor quizartinib is extremely promising as a monotherapy for patients with FLT3-ITD–positive relapsed acute myeloid leukemia.
February 08, 2017
Article
The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma, according to a recent study presented at the 2016 Society for Melanoma Research Congress.
January 06, 2017
Article
Tanios Bekaii-Saab, MD, discusses questions regarding regorafenib and TAS-102 in mCRC, compares the mechanisms of action and toxicities of both therapies, and shares his views on the optimal sequencing of the 2 agents.
December 23, 2016
Article
Alan P. Venook, MD, discusses several of the big queries that remain in mCRC and the possible explanations for survival differences between left- and right-sided tumors. He also explained how answering these questions could pave the way for more novel treatment approaches.